Patents by Inventor Andrei Raibekas

Andrei Raibekas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF REDUCING AGGREGATION OF IL-1RA
    Publication number: 20210121571
    Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.
    Type: Application
    Filed: July 31, 2020
    Publication date: April 29, 2021
    Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Inventors: Andrei RAIBEKAS, Bruce KERWIN
  • Methods of reducing aggregation of IL-1ra
    Patent number: 10765747
    Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: September 8, 2020
    Assignee: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Inventors: Andrei Raibekas, Bruce Kerwin
  • DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF
    Publication number: 20170298110
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: February 27, 2017
    Publication date: October 19, 2017
    Inventors: John W. COMMISSIONG, Andrei A. RAIBEKAS
  • Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof
    Publication number: 20160152673
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: June 30, 2015
    Publication date: June 2, 2016
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • Dopaminergic neuronal survival-promoting factors and uses thereof
    Patent number: 9115208
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: August 25, 2015
    Assignee: AMARANTUS THERAPEUTICS, INC.
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF
    Publication number: 20130078220
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: November 28, 2011
    Publication date: March 28, 2013
    Inventors: JOHN W. COMMISSIONG, ANDREI A. RAIBEKAS
  • Dopaminergic neuronal survival-promoting factors and uses thereof
    Patent number: 8084425
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: December 27, 2011
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • REVERSIBLE GEL PROTEIN FORMULATION
    Publication number: 20110223156
    Abstract: Reversible gel protein formulations, including pharmaceutical formulations, that inhibit protein aggregate formation are described, along with containers, e.g., a vial, ampoule or bottle; or an apparatus or device, e.g., a syringe, comprising such formulations. Also described are methods for inhibiting protein aggregation in a protein-containing sample and methods for inhibiting particle formation in a protein-containing sample.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 15, 2011
    Inventor: Andrei A. Raibekas
  • DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF
    Publication number: 20100119491
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: August 4, 2009
    Publication date: May 13, 2010
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • IL-1ra variants
    Patent number: 7619066
    Abstract: The present invention provides for an IL-1ra having reduced aggregation, methods of reducing aggregation of IL-1ra, and kits comprising an IL-1ra having reduced aggregation.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: November 17, 2009
    Assignee: Amgen Inc.
    Inventors: Andrei Raibekas, Bruce Kerwin
  • Methods of reducing aggregation of IL-1ra
    Publication number: 20070098684
    Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.
    Type: Application
    Filed: April 1, 2005
    Publication date: May 3, 2007
    Inventors: Andrei Raibekas, Bruce Kerwin
  • IL-1ra variants
    Publication number: 20050282752
    Abstract: The present invention provides for an IL-1ra having reduced aggregation, methods of reducing aggregation of IL-1ra, and kits comprising an IL-1ra having reduced aggregation.
    Type: Application
    Filed: April 1, 2005
    Publication date: December 22, 2005
    Inventors: Andrei Raibekas, Bruce Kerwin
  • Methods of reducing aggregation of IL-1ra
    Publication number: 20050271618
    Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.
    Type: Application
    Filed: April 1, 2005
    Publication date: December 8, 2005
    Inventors: Andrei Raibekas, Bruce Kerwin
  • Dopaminergic neuronal survival-promoting factors and uses thereof
    Publication number: 20020182198
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: March 20, 2002
    Publication date: December 5, 2002
    Inventors: John W. Commissiong, Andrei A. Raibekas